Efficacy and safety of tenapanor in hemodialysis patients with hyperphosphatemia: A systematic review and meta-analysis of randomized placebo-controlled trials.
Tenapanor
chronic kidney disease
hemodialysis
hyperphosphatemia
meta-analysis
placebo-controlled trials
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
30
05
2023
received:
26
04
2023
accepted:
13
06
2023
medline:
5
9
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
The effects of tenapanor in reducing serum phosphorus in hemodialysis patients with hyperphosphatemia are uncertain and no relevant meta-analysis has been conducted. We performed a meta-analysis of randomized placebo-controlled trials to evaluate the efficacy and safety of tenapanor. All randomized controlled trials of tenapanor were searched up to 1 August 2022. The primary endpoint was the change in serum phosphorus level from baseline with tenapanor and placebo. Data on drug-related adverse events (AEs), gastrointestinal AEs and diarrhea were collected to determine the safety of tenapanor. There were 533 patients throughout five trials that were eligible. Tenapanor significantly lowered blood phosphorus level by 1.79 mg/dl in the mean difference than the placebo. Diarrhea, gastrointestinal AEs, and drug-related AEs were more severe than placebo. This meta-analysis showed that although drug side effects were common, tenapanor significantly reduced serum phosphorus level in hemodialysis patients.
Sections du résumé
BACKGROUND
BACKGROUND
The effects of tenapanor in reducing serum phosphorus in hemodialysis patients with hyperphosphatemia are uncertain and no relevant meta-analysis has been conducted. We performed a meta-analysis of randomized placebo-controlled trials to evaluate the efficacy and safety of tenapanor.
METHODS
METHODS
All randomized controlled trials of tenapanor were searched up to 1 August 2022. The primary endpoint was the change in serum phosphorus level from baseline with tenapanor and placebo. Data on drug-related adverse events (AEs), gastrointestinal AEs and diarrhea were collected to determine the safety of tenapanor.
RESULTS
RESULTS
There were 533 patients throughout five trials that were eligible. Tenapanor significantly lowered blood phosphorus level by 1.79 mg/dl in the mean difference than the placebo. Diarrhea, gastrointestinal AEs, and drug-related AEs were more severe than placebo.
CONCLUSIONS
CONCLUSIONS
This meta-analysis showed that although drug side effects were common, tenapanor significantly reduced serum phosphorus level in hemodialysis patients.
Identifiants
pubmed: 37349983
doi: 10.1111/1744-9987.14028
doi:
Substances chimiques
tenapanor
WYD79216A6
Phosphorus
27YLU75U4W
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-847Subventions
Organisme : The General Hospital of Western Theater Command, The Military Medical Research Program
ID : 2021-XAYG-B19
Informations de copyright
© 2023 International Society for Apheresis and Japanese Society for Apheresis.
Références
Vervloet MG, Sezer S, Massy ZA, et al. The role of phosphate in kidney disease. Nat Rev Nephrol. 2017;13:27-38. https://doi.org/10.1038/nrneph.2016.164
Reiss AB, Miyawaki N, Moon J, Kasselman LJ, Voloshyna I, D'Avino R Jr, et al. CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies. Atherosclerosis. 2018;278:49-59. https://doi.org/10.1016/j.atherosclerosis.2018.08.046
Michishita R, Matsuda T, Kawakami S, Tanaka S, Kiyonaga A, Tanaka H, et al. Hypertension and hyperglycemia and the combination thereof enhances the incidence of chronic kidney disease (CKD) in middle-aged and older males. Clin Exp Hypertens. 2017;39:645-54. https://doi.org/10.1080/10641963.2017.1306541
Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74:1823-38. https://doi.org/10.1016/j.jacc.2019.08.1017
Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771-80. https://doi.org/10.1038/sj.ki.5001514
Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-8. https://doi.org/10.1681/ASN.2004070602
Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008;52:519-30. https://doi.org/10.1053/j.ajkd.2008.03.020
Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1-59. 2011;7:e1. https://doi.org/10.1016/j.kisu.2017.10.001
Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update. Am J Kidney Dis. 2020;76:S1-S107. https://doi.org/10.1053/j.ajkd.2020.05.006
Bobeck EA, Meyer KM, Helvig C, Petkovich M, Cook ME. Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1alpha-hydroxy cholecalciferol. J Ren Nutr. 2013;23:21-7. https://doi.org/10.1053/j.jrn.2011.12.005
Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int. 2016;20:38-49. https://doi.org/10.1111/hdi.12315
King AJ, Siegel M, He Y, Nie B, Wang J, Koo-McCoy S, et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Sci Transl Med. 2018;10:10. https://doi.org/10.1126/scitranslmed.aam6474
Johansson S, Rosenbaum DP, Palm J, Stefansson B, Knutsson M, Lisbon EA, et al. Tenapanor administration and the activity of the H(+)-coupled transporter PepT1 in healthy volunteers. Br J Clin Pharmacol. 2017;83:2008-14. https://doi.org/10.1111/bcp.13313
Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-response of Tenapanor in patients with hyperphosphatemia undergoing hemodialysis in Japan-a phase 2 randomized trial. Kidney Int Rep. 2022;7:177-88. https://doi.org/10.1016/j.ekir.2021.11.008
Shigematsu T, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Therapeutic effects of add-on Tenapanor for hemodialysis patients with refractory hyperphosphatemia. Am J Nephrol. 2021;52:496-506. https://doi.org/10.1159/000516156
Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. A randomized trial of Tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol. 2021;32:1465-73. https://doi.org/10.1681/ASN.2020101398
Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Åstrand M, Johansson S, Knutsson M, et al. Effect of Tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28:1933-42. https://doi.org/10.1681/ASN.2016080855
Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of Tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol. 2019;30:641-52. https://doi.org/10.1681/ASN.2018080832
Medscape MN. FDA Rejects tenapanor for control of phosphorus in kidney disease. 2021 https://www.medscape.com/viewarticle/956066
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https://doi.org/10.1136/bmj.b2700
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788-93. https://doi.org/10.1681/ASN.2004040275
Shang D, Xie Q, Ge X, Yan H, Tian J, Kuang D, et al. Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients. BMC Nephrol. 2015;16:107. https://doi.org/10.1186/s12882-015-0103-8
Airy M, Schold JD, Jolly SE, Arrigain S, Bansal N, Winkelmayer WC, et al. Cause-specific mortality in patients with chronic kidney disease and atrial fibrillation. Am J Nephrol. 2018;48:36-45. https://doi.org/10.1159/000491023
Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (cardiovascular health study). J Am Coll Cardiol. 2012;60:200-7. https://doi.org/10.1016/j.jacc.2012.03.040
Almqvist EG, Bondeson AG, Bondeson L, Nissborg A, Smedgard P, Svensson SE. Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery. 2002;132:1126-32; discussion 32. https://doi.org/10.1067/msy.2002.128692
Kidney Disease: Improving Global Outcomes CKDMBDUWG. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7:1-59. https://doi.org/10.1016/j.kisu.2017.04.001
Shinaberger CS, Greenland S, Kopple JD, van Wyck D, Mehrotra R, Kovesdy CP, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88:1511-8. https://doi.org/10.3945/ajcn.2008.26665
Phosphate Binder Use, Last 3 Months: DOPPS Practice Monitor; 2020. https://www.dopps.org/DPM-HD/Files/maxPBINDER_use_c_overallTAB.htm.
Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis. 2009;54:619-37. https://doi.org/10.1053/j.ajkd.2009.06.004
Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2. https://doi.org/10.1186/1471-2369-9-2
Johansson S, Leonsson-Zachrisson M, Knutsson M, Spencer AG, Labonté ED, Deshpande D, et al. Preclinical and healthy volunteer studies of potential drug-drug interactions between Tenapanor and phosphate binders. Clin Pharmacol Drug Dev. 2017;6:448-56. https://doi.org/10.1002/cpdd.307
Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21:407-16. https://doi.org/10.1007/s10157-016-1302-8
Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312-24. https://doi.org/10.1056/NEJMra0912522
Block GA, Bleyer AJ, Silva AL, Weiner DE, Lynn RI, Yang Y, et al. Safety and efficacy of Tenapanor for long-term serum phosphate control in maintenance dialysis: a 52-week randomized phase 3 trial (PHREEDOM). Kidney360. 2021;2(10):1600-10. https://doi.org/10.34067/KID.0002002021